Mandate

Vinge advises Surgical Science Sweden AB (publ) in connection with the acquisition of Mimic Technologies Inc and with a directed share issue

January 26, 2021 M&A

Vinge has advised Surgical Science Sweden AB (publ) (“Surgical Science”) in connection with its acquisition of all shares in Mimic Technologies Inc for an initial consideration of SEK 150 million with a maximum deferred contingent consideration of SEK 130 million.

In order to finance the acquisition, Surgical Science has carried out a directed share issue. The directed share issue comprised of 3,279,676 newly issued shares at a subscription price of SEK 98.30 per share, whereby Surgical Science will receive gross proceeds of approximately SEK 322 million before transaction related costs. The subscription price has been determined through an accelerated book‑building procedure and corresponds to a premium of approximately 1 per cent to the closing price of SEK 97.40 per share on 20 January 2021 on Nasdaq First North Growth Market.

Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Vinge’s team has consisted of Fredrik Sonander (M&A) and Edin Agic (Capital Markets).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025